Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DosEmi: Pharmacokinetic-guided dosing of emicizumab in congenital hemophilia A
2021-004039-10Phase 4Active
- Sponsor
- University Medical Center Utrecht
- Start
- Jan 2022
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, randomised trial of emicizumab in hemophilia A (2 arms), sponsored by University Medical Center Utrecht. Primary endpoint: Primary: Bleeding outcomes. Started Jan 2022; status: active.
02
Drugs
emicizumab
03
Conditions
hemophilia A
Beyond the preview
Go deeper on 2021-004039-10.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-004039-10.